Homeopathic medicines for fibromyalgia in adults: A randomized exploratory trial

Published: 3 November 2026| Version 1 | DOI: 10.17632/j2fwchm5yt.1
Contributors:
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,

Description

Fibromyalgia is a chronic multisymptomatic disorder associated with substantial functional impairment and diminished quality of life. Evidence concerning individualized homeopathic medicines (IHMs) remains limited. This exploratory trial investigated preliminary treatment effects and the safety of IHMs against placebo. This single-center, randomized, double-blind, placebo-controlled exploratory trial allocated 54 participants (IHMs, n = 36; placebo, n = 18) in a 2:1 ratio. Both groups received supportive care and were followed monthly for three months. The primary outcome was change in total Revised Fibromyalgia Impact Questionnaire (FIQR) score. Secondary outcomes included PROM-FM components and MYMOP2. Intention-to-treat analyses incorporated baseline adjustment and multiplicity correction. Longitudinal models evaluated symptom trajectories. Both groups demonstrated substantial within-group reductions in total FIQR scores over three months, with mean reductions of 22.95 and 22.05 points in the IHMs and placebo groups, respectively. The observed between-group difference was negligible, with a small effect size and no statistically significant difference after multiplicity adjustment (0.90 points, Hedges’ g = −0.07, adjusted p = 0.932). Secondary outcomes and longitudinal analyses similarly provided no convincing evidence of differential treatment trajectories. Exploratory moderator analyses suggested potential heterogeneity but remain hypothesis-generating. Two mild adverse events occurred in the IHMs group and resolved completely. This underpowered exploratory trial did not provide convincing evidence of a between-group benefit. However, the limited statistical power (approximately 41%) and associated uncertainty preclude definitive conclusions regarding efficacy or its absence. The findings provide preliminary estimates to inform future adequately powered, confirmatory trials with longer follow-up.

Files

Institutions

Categories

Fibromyalgia, Homeopathy, Randomized Clinical Trial

Licence